Hansoh BioMedical RD Company
Cisplatin / carboplatin(Hansoh BioMedical R&D Company)은 Advanced Solid Tumors 표적 ADC로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: Targeting the ERRα/LDHA pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 84% (ClinicalTrials.gov NCT04194944). 차별점: novel drug carriers.
Advanced Solid Tumors
Advanced Solid Tumors
Recruiting
ADCs to treat OC
vedotin with pembrolizumab
Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer
novel drug carriers
Targeting the ERRα/LDHA pathway
apoptosis (flow cytometry), and gene expression by reverse transcription quantitative polymerase chain reaction (RT-qPCR) includi
PD-L1 expression
resistance mechanisms in cervical cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hansoh BioMedical RD Company
Cisplatin / carboplatin(Hansoh BioMedical R&D Company)은 Advanced Solid Tumors 표적 ADC로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: Targeting the ERRα/LDHA pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 84% (ClinicalTrials.gov NCT04194944). 차별점: novel drug carriers.
Advanced Solid Tumors
Advanced Solid Tumors
Recruiting
ADCs to treat OC
vedotin with pembrolizumab
Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer
novel drug carriers
Targeting the ERRα/LDHA pathway
apoptosis (flow cytometry), and gene expression by reverse transcription quantitative polymerase chain reaction (RT-qPCR) includi
PD-L1 expression
resistance mechanisms in cervical cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.